Glycotope, a German clinical-stage immuno-oncology company built on its glyco-biology expertise, has appointed Dr Alfredo Zurlo as Chief Medical Officer.
Dr Zurlo is an oncologist with many years of clinical experience and a track record in the pharmaceutical and biotechnology industries. His last role was at Mologen where he was Chief Medical Officer and a Member of the Executive Board.
Previously he held various positions at F Hoffmann La Roche and Roche SA, including Senior International Medical Leader Director Oncology and Medical Director Oncology. Before that, he was a medical advisor for the European Organisation for the Research and Treatment of Cancer (EORTC). Dr Zurlo completed his oncology and radio oncology training at the University of Rome.
Dr Zurlo said: 'I am excited to be joining Glycotope. The company has a unique approach to the development of novel immuno-oncology candidates. Its proprietary glyco-biology platforms allow the generation of monoclonal antibodies with fully human glycosylation improving activity, drug characteristics and side effect profiles. Glycotope can also target carbohydrate epitopes to generate highly specific, novel targets. I very much look forward to working with the team to maximise the clinical potential of this powerful technology base.'
